Last Update 08 Jun 26

Fair value Decreased 7.61%

ISRG: Future Returns Will Depend On Procedure Utilization Outpacing Sector Rotation Headwinds

Intuitive Surgical's updated analyst price target has moved lower in line with a reset of fair value from $611.82 to $565.25, as analysts factor in a sector wide pullback in medtech valuations, slightly softer revenue growth assumptions, modestly adjusted discount rates, and a revised future P/E of 53.19 while still citing company specific earnings leverage and product positioning in their broader rationale.

Analyst Commentary

Recent research on Intuitive Surgical highlights a mix of optimism on long term growth potential and caution around sector specific headwinds and valuation reset. Price targets have generally been revised lower as analysts factor in weaker medtech sentiment and updated assumptions, but opinions on the stock's risk reward profile remain split.

Bullish Takeaways

Bullish analysts point to Intuitive Surgical's earnings leverage and product positioning as key supports for the updated fair value and longer term growth thesis, even with a reduced future P/E framework.
Some bullish analysts maintain Buy ratings alongside trimmed price targets, suggesting they still see upside potential relative to the new medtech valuation range despite sector pressure.
Commentary around the broader U.S. medical technology space includes views that fundamentals remain healthy. In their view, this supports the case for Intuitive Surgical to continue growing and scaling earnings over time.
Intuitive Surgical was recently upgraded to Buy by a major bank with a US$590 price target. The argument is that the recent selloff has made the stock more appealing for investors who are comfortable with the sector's risk profile.

Bearish Takeaways

Bearish analysts have cut price targets and, in at least one case, kept a Sell rating, signaling concern that the stock could still be pricing in too much optimism relative to current sector conditions.
Research notes describe medtech as having gone through one of its weakest multi decade stretches in performance, valuation, and outlook revisions. This raises questions about how quickly sentiment on the group can improve.
Sector commentary flags slower growth, reimbursement and competitive risks, and aging investment narratives as headwinds that could limit multiple expansion or pressure earnings expectations for Intuitive Surgical alongside peers.
Some analysts refer to a "new reality of medtech valuations" in a year of few product cycles, ACA and utilization worries, inflation concerns, and capital flowing to data centers over healthcare. All of these factors feed into more conservative targets for the stock.

What's in the News

Reported Q1 2026 revenue of US$2.77b, up 23% year over year, with adjusted EPS of US$2.50 that was 20% above consensus, and total surgical procedures up about 17%, driven by the da Vinci 5 and Ion platforms (source: "Intuitive Surgical Reports Strong Q1 2026 Earnings, Raises Full-Year Procedure Growth Outlook Amid Competitive Headwinds").
Raised full year 2026 global da Vinci procedure growth outlook to a range of 13.5% to 15.5%, with recurring revenue at 86% of total revenue and adjusted operating margin at 38.4% (source: same as above).
Launched more than 100 upgrades to the da Vinci 5 system, including extending Force Feedback instrument use from 6 to 15 uses, new telepresence features, security and reliability improvements, and surgeon workflow tools such as mobile login and SimNow 2. These are supported by a dV5 Complete Care plan that targets 98% uptime and reports over 99% uptime on an installed base of more than 1,400 systems (source: "Intuitive Surgical Unveils Over 100 Upgrades to da Vinci 5, Including Extended Force Feedback Instrument Use").
Outlined a digital roadmap focused on surgical data, AI and connected workflows, with plans for decision support, workflow optimization, advanced surgical assistance and telesurgery. The company plans to use data from the installed base to support future AI models and products over the next three to five years (source: "Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?").
Initiated several voluntary recalls on da Vinci S and Si instruments and SureForm reloads, including Class I and Class II FDA classifications. These actions are tied to risks such as incomplete staple lines and increased complaints of broken or frayed cables, with worldwide distribution and recalls currently ongoing (source: FDA enforcement and recall reports for 2025 to 2026).

Valuation Changes

Fair Value: reset lower from $611.82 to $565.25, reflecting a modest reduction in the implied upside that analysts are using in their models.
Discount Rate: adjusted slightly lower from 7.67% to 7.44%, suggesting a small change in assumptions around risk and required return.
Revenue Growth: trimmed from 13.83% to 13.09%, indicating a slightly more conservative view on future top line expansion.
Net Profit Margin: nudged higher from 29.31% to 29.37%, pointing to marginally stronger expected earnings efficiency.
Future P/E: reduced from 60.56x to 53.19x, implying a lower valuation multiple being applied to expected earnings.

12 views

Key Takeaways

Expanding global adoption and procedure diversity, coupled with innovative products and digital tools, are fueling recurring revenues, margin stability, and long-term competitive advantage.
Increasing regulatory and payer support, driven by strong clinical outcomes, is reducing adoption barriers and supporting durable growth across multiple healthcare markets.
Expansion and revenue growth are challenged by international budget constraints, trade uncertainties, increased competition, regulatory delays, and shifting healthcare reimbursement policies.

Catalysts

About Intuitive Surgical

Develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Strong global procedure growth (18% total; 17% da Vinci specifically), increasing installed base, and rising system utilization indicate that Intuitive is effectively capturing surging demand for minimally invasive, robotic-assisted surgeries as chronic disease rates rise and populations age globally-directly supporting long-term recurring revenue and margin stability.
Strategic expansion into emerging markets (notably India, Korea, Brazil, Southeast Asia) and broader adoption beyond core urology into general, thoracic, colorectal, and other complex procedures is increasing the addressable market, supporting sustainable topline growth and diversification of revenue streams.
Ongoing product innovation (including full launch of da Vinci 5, integrated force feedback, and digital/AI case insights), coupled with R&D to expand into adjacent specialties, enhances clinical outcomes and surgeon efficiency-supporting future procedure growth, higher system ASPs, and increased recurring instrument and accessory revenues.
Accelerated adoption of digital and telecollaboration tools as healthcare systems modernize, alongside increased training and surgeon acceptance, should further drive utilization rates per installed system and strengthen Intuitive's long-term competitive advantage, positively impacting operating leverage and net margins.
Compelling clinical data showing superior long-term outcomes for robotic-assisted surgeries (e.g., lower recurrence rates in cancer) is likely to underpin broader regulatory and payer support for robotic approaches-reducing barriers to adoption and increasing utilization, which should drive durable revenue and earnings growth.

Intuitive Surgical Earnings and Revenue Growth

Intuitive Surgical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Intuitive Surgical's revenue will grow by 13.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 28.2% today to 29.4% in 3 years time.
Analysts expect earnings to reach $4.5 billion (and earnings per share of $11.64) by about June 2029, up from $3.0 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $5.0 billion in earnings, and the most bearish expecting $4.0 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 53.3x on those 2029 earnings, up from 50.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.3x.
Analysts expect the number of shares outstanding to decline by 1.2% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.44%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing financial and budgetary pressures in key international markets like Japan, China, and Europe-driven by government budget deficits, healthcare spending constraints, and capital expenditure limitations-continue to limit Intuitive Surgical's expansion in those regions, potentially slowing system placements and long-term revenue growth.
Rising tariff and trade uncertainty, especially related to U.S.-China relations and global supply chain challenges, could increase cost of sales and compress gross margins; with tariff impacts expected to rise further, prolonged or worsening trade tensions could significantly impact profitability.
Increasing competition from third-party suppliers offering remanufactured or extended-use instruments threatens the high-margin recurring revenue from Intuitive's consumables, and if hospitals adopt these alternatives to cut costs, this could erode predictability and volume of recurring revenue, ultimately pressuring net earnings.
Persistently constrained adoption rates or measured rollouts of new technologies (such as da Vinci 5 in Europe/Japan due to regulatory delays, lack of Force Feedback approval, or higher system pricing) may extend upgrade cycles and reduce the pace of both new and replacement system sales, dampening revenue and margin expansion.
Uncertainty around evolving U.S. fiscal and reimbursement policy (e.g., potential loss of Medicaid coverage for millions of Americans, value-based care models, and increased focus on procedure cost-effectiveness) could negatively influence hospital budgets, reimbursement rates, and procedural demand, placing downward pressure on both utilization rates and overall company revenue.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $565.25 for Intuitive Surgical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $750.0, and the most bearish reporting a price target of just $366.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $15.3 billion, earnings will come to $4.5 billion, and it would be trading on a PE ratio of 53.3x, assuming you use a discount rate of 7.4%.
Given the current share price of $422.06, the analyst price target of $565.25 is 25.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Intuitive Surgical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rising Demand And Cost Pressures Will Shape Robotic Surgery Outlook